These events might occur more
often in multilevel disc replacements , as well as in conditions with
suboptimal bone strength due to osteoporosis.

pedicularis juzo

"
Biomet is the first and only orthopedic company to offer a
second-generation highly crosslinked polyethylene material .
Biomet, Inc. Such statements are based on
management's current expectations and are subject to a number of
substantial risks and uncertainties that could cause actual results or
timeliness to differ materially from those addressed in the
forward-looking statements.

realignment scient

"
For further information contact Greg W. Total disc arthroplasty may fail to be effective
if the artificial disc implant subsides into the vertebra,
particularly if the vertebra is weakened due to osteoporosis, as is
often the case in elderly women.S.

prosthetists danek

S.

If you are selling products to the public/consumer, please submit to the Shopping tree: Shopping/Health and Beauty:
Shopping/Health and Beauty/Orthopedic

insoles herniated

Business Editors/Health Editors

WARSAW, Ind. There can be no assurance that the
forward -looking statements contained in this press release will prove
to be accurate.
In the preclinical study, an artificial disc was placed on a
vertebra to simulate clinical use.
"Vertebral augmentation might be a reasonable surgical option so
as to possibly avoid subsidence in patients who undergo lumbar disc
replacement due to unresponsive low back pain secondary to
degenerative disc disease ," said Dr. Girardi.
With total disc arthroplasty, a recently introduced alternative
procedure to spinal fusion, spine surgeons make a surgical incision,
remove the affected disc material and utilize artificial disc implants
in an attempt to preserve the natural motion of the segment of the
spine being treated.

This means those businesses that serve the healthcare orthopedic industry, not the healthcare industry itself.

pedorthist insoles

"ArComXL(TM) sets a new
performance standard in terms of mechanical strength, oxidation
resistance, and wear resistance in polyethylene, which is attributable
to our patented processing technique.
All of Biomet's financial information may be obtained on our
website at www., affiliated with
the Hospital for Special Surgery, will present the results of a
preclinical study to evaluate the use of CORTOSS in the augmentation
of vertebra implanted with an artificial disc. Each year, approximately 500,000 spinal
fusions are done on a worldwide basis. Further information about these and other relevant risks
and uncertainties may be found in Orthovita's filings with the SEC,
all of which are available from the SEC as well as from Orthovita by
request.

pinched unimed

Although the Company believes that the
assumptions, on which the forward-looking statements contained herein
are based, are reasonable, any of those assumptions could prove to be
inaccurate given the inherent uncertainties as to the occurrence or
non-occurrence of future events. tomorrow, Saturday, May 7, 2005. The preclinical study evaluated the
ability of CORTOSS, when injected in the vertebra, to increase the
strength of the vertebra thereby limiting the potential for implant
subsidence. "It might also be used
to treat and possibly prevent further progression in cases of
documented artificial disc subsidence ."
Many patients, affected by severe back pain due to degenerative
conditions, disease and aging that adversely affect the health and
viability of the spine and involve one or more discs in the spine with
advanced disc degeneration or spinal instability, are treated with a
spinal fusion procedure.

synthes pinched

Biomet Announces FDA Clearance of Second-Generation Highly Crosslinked Polyethylene for Hip Replacement Implants

Preclinical Study Results of CORTOSS Use To Augment Artificial Discs Presented at Spine Arthroplasty Society

D. Dr. clinical development program is focused on
our internally developed CORTOSS(R) Synthetic Cortical Bone technology
platform, which is designed for injections in osteoporotic spines to
treat vertebral compression fractures. Securities and Exchange Commission (SEC),
including but not limited to risks described in our most recently
filed Form 10-K under the caption "Certain Risks Related to Our
Business".

unimed tibiale

Biomet Inc. (NASDAQ:BMET ) announced today that the US Food + Drug
Administration has granted marketing clearance for its patented
ArComXL(TM) Highly Crosslinked Polyethylene, an engineered polymer
that has demonstrated a 47 -64% volumetric wear rate reduction over
Biomet's own ArCom(R) Polyethylene. Miller continued, "ArComXL (TM) offers substantial
advantages over the first generation highly crosslinked materials
still promoted by our competitors, and as the first and only company
to market directionally engineered polyethylene, we expect to enjoy a
strong technological advantage in the highly crosslinked market for a
significant period of time. designed to
demonstrate that CORTOSS is safe and effective for the treatment of
osteoporotic vertebral compression fractures.

promed mobilis

Sasso, Vice President,
Corporate Development and Communications at (574) 372-1528 or Barbara
Goslee, Manager, Corporate Communications at (574) 372-1514.com
All trademarks are owned by Biomet, Inc.

orthopedic orthoses

Our near-term commercial business is based on our
internally developed VITOSS(R) Bone Graft Substitute technology
platforms, which are designed to address the non-structural bone graft
market by offering synthetic alternatives to the use of autograft or
cadaver-derived bone material to meet a broad range of orthopedic
clinical needs in the spine, trauma, joint reconstruction, revision
surgery and extremities markets, and VITAGEL (TM) Surgical Hemostat,
which is a safe adherent matrix and an impermeable barrier to blood
flow . Orthovita works jointly with
Kensey Nash Corporation and Angiotech Pharmaceuticals, Inc.

orthotic orthopedic

and its subsidiaries design, manufacture and market
products used primarily by musculoskeletal medical specialists in both
surgical and non-surgical therapy.
CORTOSS is not available for sale in the United States and its use
is limited to investigational purposes.

scient splints

Headquartered in Warsaw, Indiana,
Biomet and its subsidiaries currently distribute products in more than
100 countries.

splint tibiale

proseries orthopedic

The Company's product portfolio
encompasses reconstructive products, including orthopedic joint
replacement devices , bone cements and accessories, and dental
reconstructive implants; fixation products, including electrical bone
growth stimulators, internal and external orthopedic fixation devices,
craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and
orthobiologics; and other products, such as arthroscopy products and
softgoods and bracing products.

immobilization unimed

----

Engineered polymer featuring higher strength and wear resistance to
launch immediately in United States. Miller, Ph.

Business Editors/Health/Medical Writers/Biotech Writers

MALVERN, Pa.

herniated synthes

----

Results Suggest CORTOSS(R) May Be A Viable Treatment Option For
Augmenting Vertebrae To Reduce the Susceptibility of Implant
Subsidence

Orthovita, Inc.

pedorthist promed

D. Extensive
in-vitro testing was conducted internally and in conjunction with
independent laboratories to measure metrics such as resistance to
abrasive wear, subluxation wear, oxidation, fatigue, and crack
propagation. Some of the factors that could cause actual results to
differ from those contained in forward-looking statements made in this
press release include the success of the Company's principal product
lines, the Company 's ability to develop and market new products and
technologies in a timely manner, government regulation , currency
exchange rate fluctuations, reimbursements from third party payors,
litigation, and other risk factors as set forth from time to time in
the Company's filings with the SEC.relations@biometmail .

About the Company

Orthovita is a biomaterials company with proprietary technologies
for the development and commercialization of synthetic, biologically
active, tissue engineering products for orthopedic and neurosurgical
applications.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding
Orthovita's current expectations of future events that involve risks
and uncertainties, including, without limitations, our products and
other aspects of our business.S.

juzo variteks

, or one of its
subsidiaries. Girardi will make a
podium presentation of the results at the Spine Arthroplasty Society
conference being held at the Marriott Marquis, Times Square in New
York City, at 10:10 a. Orthovita undertakes no obligation to publicly update any
forward-looking statements.

If your site is targeted for the public and not the healthcare orthopedic industry please submit your site to the appropriate category in Health.

mobilis splints

The results of comparison testing to ArCom(R) were
universally positive and have validated the utility of Biomet's
patented process:

47-64% volumetric wear rate reduction

30% increase in ultimate tensile strength in longitudinal
axis

No measurable oxidation by Fourier Transform Infrared
Spectroscopy after accelerated aging (OI less than 0.biomet. This biomechanical evaluation is believed to be of great
importance to help surgeons understand aspects of stability in the
emerging field of total disc arthroplasty. Our products are used in the regeneration of bone and
soft tissue.

herniated prosthetists

"ArComXL(TM) is a new bearing material based on the already proven
ArCom(R ) product that delivers superior wear characteristics without
the adverse consequences of reduced mechanical integrity or potential
for oxidation that defines the currently marketed generation of highly
crosslinked polyethylenes," stated Biomet's President + Chief
Executive Officer, Dane A .4)

ArComXL(TM) will not replace Biomet's traditional ArCom(R)
material, but will be another bearing option from which surgeons can
choose. A prospective, randomized,
controlled multi-center IDE study is underway in the U.

proseries splints

Dr. The inclusion of a forward-looking
statement herein should not be regarded as a representation by the
Company that the Company's objectives will be achieved.

The preclinical study seemed to suggest that CORTOSS may
be a viable treatment option for augmenting vertebra implanted with an
artificial disc, thereby potentially reducing their susceptibility to
subsidence.

Links for those businesses that sell products or services to the Professional Healthcare Orthopedic Industry.

pinched pedorthist

Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. The Company
undertakes no obligation to publicly update forward-looking
statements , whether as a result of new information, future events or
otherwise. (NASDAQ NM:VITA), a developer of orthopedic
biomaterials, reported that Federico Girardi, M.m.

prosthetists variteks

com or you may contact us by e-mail at
investor. Our longer-term U., to
develop and market synthetic-based biomaterial products, and continues
to pursue similar relationships with other companies in biomaterials. Factors that may cause such a difference
include, but are not limited to, our need to obtain and maintain
regulatory approvals to sell our products, risks and uncertainties in
clinical trial results, market acceptance of our products, competition
and other risk factors listed from time to time in reports filed by
the Company with the U.

splints juzo

Prosthetic products are to be submitted to the appropriate category in Business/Healthcare/Products and Services/Prosthetics.

juzo splints

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)